Third Annual Korean Medical and Healthcare Company Showcase

Korean healthcare companies are developing advanced technologies, powering the next generation of medical devices and healthcare innovation. Join MATTER and KOSME to hear from the four Korean companies participating in the U.S. Market Adoption Program share how their solutions are driving innovation and meeting the future needs of the healthcare industry and its patients. Join us for virtual networking after the pitches to meet the participating companies and fellow healthcare innovators.

Agenda:

4:00–4:15pm CT | Welcome remarks from MATTER and KOSME

4:15–4:35pm CT | Korean company presentations

4:35–5:00pm CT | Virtual networking

ABOUT THE COMPANIES:

Deep Bio

Deep Bio is an AI healthcare company that provides solutions for unmet medical needs using deep learning technology with a focus on digital pathology. Currently, using a convolutional neural network with the input of myriad needle biopsy images, they are developing a computer-aided detection and diagnosis system for prostate cancer.

Medipixel

Medipixel was established in 2017 as a company that contributes to the improvement of the quality of human life by innovating diagnostic and therapeutic procedures in cardiovascular disease with the power of AI. Medipixel has the best expertise in AI technology for computer vision, deep learning and reinforcement learning, with their Medipixel XA Series having received FDA 510(k) and Korean Ministry of Food and Drug Safety (MFDS) approval and their FFRXA currently undergoing clinical trials for MFDS approval.

PROTEINA

PROTEINA has developed the first-in-class single-molecule, co-immunoprecipitation-based general platform, which enables precise measurement of protein-protein interactions (PPIs) at the single-molecular level. Their wealth of knowledge of and experience with the intricacies of PPIs is reflected in their diverse range of research services and products, including biomarker discovery for drug development, deciphering the mechanisms of pharmaceutical compounds and identifying the ideal drug dose of a specific drug treatment. PROTEINA has seen their goal of developing accurate, reliable companion diagnostic devices slowly become a reality.

VUNO

VUNO is an AI medical software company that develops deep learning-based medical AI solutions using medical imaging (X-ray, CT, MRI) and biosignal data. VUNO strives to support medical practitioners in their day-to-day workflows, empowering them to make better diagnostic decisions faster and more accurately and to improve quality of patient care, monitoring and treatment planning. VUNO Med®–DeepCARS™ is an AI-based patient cardiac arrest risk management system for cardiac arrest monitoring and risk prediction that received Breakthrough Device Designation from the FDA earlier this month.